Deutsche Bank reissued their buy rating on shares of AstraZeneca (LON:AZN) in a report published on Tuesday, September 25th, MarketBeat reports. The firm currently has a GBX 6,000 ($78.40) target price on the biopharmaceutical company’s stock.
AZN has been the subject of a number of other reports. Barclays reissued an overweight rating and issued a GBX 6,600 ($86.24) price objective (up from GBX 6,500 ($84.93)) on shares of AstraZeneca in a research report on Friday, August 10th. Credit Suisse Group set a GBX 5,900 ($77.09) price objective on shares of AstraZeneca and gave the company a buy rating in a research report on Friday, July 27th. Liberum Capital reissued a hold rating on shares of AstraZeneca in a research report on Friday, August 31st. JPMorgan Chase & Co. set a GBX 5,800 ($75.79) price objective on shares of AstraZeneca and gave the company a buy rating in a research report on Friday, July 20th. Finally, Goldman Sachs Group set a GBX 4,080 ($53.31) price objective on shares of AstraZeneca and gave the company a sell rating in a research report on Friday, August 31st. Three research analysts have rated the stock with a sell rating, seven have given a hold rating and thirteen have assigned a buy rating to the company. AstraZeneca presently has an average rating of Hold and a consensus price target of GBX 5,700.70 ($74.49).
LON AZN traded down GBX 70 ($0.91) during trading hours on Tuesday, hitting GBX 5,546 ($72.47). The company had a trading volume of 2,077,869 shares, compared to its average volume of 2,310,000. AstraZeneca has a fifty-two week low of GBX 4,260 ($55.66) and a fifty-two week high of GBX 5,520 ($72.13).
AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Read More: Investing in Growth Stocks
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.